Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

businesswire

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint – NEWSnet – News… as it used to be

More Press Releases

June 24, 2026

Mammogen Appoints Physician Executive and Breast Imaging Leader, Dr. Elise Berman, as Chief Medical Officer

Featured image for Auto-prepared featured image

June 24, 2026

ModMed Scribe 2.0 Surpasses One Million AI-Powered Patient Visits

June 24, 2026

RRC Companies Receives Investment from New Mountain Capital and Appoints Dr. Hisham Mahmoud as Chairman of the Board

June 24, 2026

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

Mammogen Appoints Physician Executive and Breast Imaging Leader, Dr. Elise Berman, as Chief Medical Officer

ModMed Scribe 2.0 Surpasses One Million AI-Powered Patient Visits

RRC Companies Receives Investment from New Mountain Capital and Appoints Dr. Hisham Mahmoud as Chairman of the Board

Automotive Thermoplastic Resin Composites Market Trend, Top Growth Companies and Industry Forecast, 2026-2033